Trial Profile
A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-122 Lotion (0.01% Halobetasol Propionate) to Ultravate (Halobetasol Propionate) Cream, in the Treatment of Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Sep 2020
Price :
$35
*
At a glance
- Drugs Ulobetasol (Primary) ; Ulobetasol (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Bausch Health Companies; Valeant Pharmaceuticals International
- 01 Jun 2019 Results assessing efficacy and safety of halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in moderate-to-severe psoriasis once-daily published in the Journal of Dermatological Treatment
- 15 Oct 2018 According to a Bausch Health Companies media release, data from this study to Present at The Fall Clinical Dermatology Conference.
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.